Cepheid ($CPHD) says it gained a key "moderate complexity" CLIA designation for its new combo TB test, helping to position the diagnostic to reach the broadest ...
Cepheid announced the U.S. Food & Drug Administration (FDA) has categorized Cepheid's Xpert® CT/NG test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA). Xpert ...
Cepheid ( CPHD) announced that its new TB test received market authorization from the U.S. Food & Drug Administration (FDA). FDA has recently categorized its Xpert MTB/RIF test as 'Moderate Complexity ...
The US Food & Drug Administration (FDA) has categorized Cepheid's Xpert MTB/RIF test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA). Xpert MTB/RIF is designed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results